Abstract The contributions of phosphorylation-mediated signaling networks to colon cancer metastasis are poorly defined. To interrogate constitutive signaling alterations in cancer progression, the global phosphoproteomes of patient-matched SW480 (primary colon tumor origin) and SW620 (lymph node metastasis) cell lines were compared with TiO 2 and immobilized metal affinity chromatography phosphopeptide enrichment followed by liquid chromatography-tandem mass spectrometry. Network analysis of the significantly altered phosphosites revealed differential regulation in cellular adhesion, mitosis, and messenger RNA translational machinery. Messenger RNA biogenesis and splicing, transport through the nuclear pores, initiation of translation, and stability and degradation were also affected. Although alterations in these processes have been associated with oncogenic transformation, control of messenger RNA stability has typically not been associated with cancer progression. Notably, the single phosphosite with the greatest relative change in SW620 cells was Ser2 on eukaryotic translation initiation factor 2 subunit 2, suggesting that SW620 cells translate faster or with greater efficiency than SW480 cells. These broad changes in the regulation of translation also occur without overexpression of eukaryotic translation initiation factor 4E. The findings suggest that metastatic cells exhibit constitutive changes to the phosphoproteome, and that messenger RNA stability and translational efficiency may be important targets of deregulation during cancer progression.
Introduction
Colorectal cancer deaths overwhelmingly result from metastasis rather than from locally confined tumors. Cancer progression is associated with invasive cellular behavior, migration, angiogenesis, and resistance to apoptosis [1] . All of these processes are regulated in part by protein phosphorylation. Significant cross talk among these pathways and other pathways facilitates both the acquisition of increasingly aggressive traits and resistance to drug treatments over time [2] [3] [4] [5] [6] . However, the relationships among these pathways and the molecular mechanisms of metastasis remain incompletely understood.
Because of the number of processes involved and the cross talk among intracellular signaling pathways, the higher-order information provided by proteomics and phosphoproteomics is particularly useful for investigating the mechanisms of metastasis. In 2012 Wiśniewski et al. [7] compared the proteomes of formalin-fixed paraffinembedded archived normal tissues and primary colon tumors from eight patients, as well as matched nodal metastases for seven of the patients. Although dramatic changes in the proteome were noted in the primary tumors compared with their matched normal tissues, the Electronic supplementary material The online version of this article (doi:10.1007/s00216-016-0125-5) contains supplementary material, which is available to authorized users. differences between the tumors and the metastases were much subtler. This nuanced discrepancy suggests that the metastatic proteomes may display more patient-to-patient variability, or that relatively few protein-level changes are needed for tumors to metastasize compared with the steps required for oncogenesis. On the other hand, posttranslational modifications may be able to account for the phenotypic differences between stage II and stage III tumors that are not explained at the proteomic level.
One particularly valuable in vitro colorectal cancer model is the SW480 and SW620 pair of cell lines, representing the chromosomal instability subtype of colorectal cancer that is commonly observed clinically [8, 9] . These patient-matched cell lines were derived from a primary adenocarcinoma and a lymph node metastasis respectively [8] . They display differences in xenograft metastatic potential [10] , migratory propensity, and drug sensitivity [11] that recapitulate behavior observed in vivo. Previous studies have compared the SW480 and SW620 cell lines at the proteome and secretome levels [12, 13] , but there has been no report on the contributions of posttranslational modifications to the metastatic phenotypes observed in SW620 cells relative to SW480 cells. Consequently, a comparison of the constitutive phosphorylation status of these two cell lines should provide a rich source of information about the unique behavior and vulnerabilities of metastatic colon cells.
To assess the relative constitutive phosphorylation in the two cell lines, we performed comparative phosphoproteomic analysis of these cells by liquid chromatography (LC)-mass spectrometry (MS). Phosphopeptides from cell lysates labeled by the stable isotope labeling of amino acids in cell culture (SILAC) method were enriched with a combined immobilized metal affinity chromatography (IMAC)-TiO 2 strategy and fractionated by high-pH reversed-phase SPE cartridges before LC-MS. Nonenriched peptides from the same lysates were similarly fractionated and analyzed by LC-MS to allow normalization of some phosphosites to protein expression changes. This discovery experiment identified altered signaling in adhesion, migration, mitosis, messenger RNA (mRNA) biogenesis, and regulation of translation. The network-level deregulation of mRNA processing is underscored by the finding that Ser2 of eukaryotic translation initiation factor 2 subunit 2 (eIF2S2) exhibited the greatest phosphorylation increase in SW620 cells. Therefore, SW620 cells appear to have a higher translational capacity than SW480 cells, and they accomplish this without overexpressing the mRNA 5′ capbinding protein eukaryotic translation initiation factor 4E (eIF4E). Taken together, these data provide new evidence that metastatic cells deregulate mRNA stability and translational efficiency with constitutive changes to the phosphoproteome.
Materials and methods

Human and animal rights
This study used established human-derived cell lines, which do not require institutional review board approval or informed consent before new research.
Cell culture and harvest
Human colorectal cancer cell lines SW480 and SW620 were purchased from American Type Culture Collection (Manassas, VA, USA) and maintained in RPMI 1640 medium (Invitrogen, Gaithersburg, MD, USA) supplemented with 10% fetal bovine serum (Thermo Scientific, Pittsburgh, PA, USA) and 2 mM L-glutamine (Invitrogen) and grown in 5% CO 2 at 37°C. The cell lines were used within 3 months after receipt or resuscitation of frozen aliquots thawed from liquid nitrogen. The provider assured the authentication of these cell lines by cytogenetic analysis.
For SILAC experiments, the SW480 and SW620 cells were cultured in SILAC RPMI 1640 media containing 10% dialyzed fetal bovine serum plus N 2 -lysine (SILAC Bheavy^) or an equal concentration of the corresponding light isotopes (SILAC Blight^). Both cell lines were expanded for more than ten doublings. Cells were harvested at 60% confluency by our scraping them in ice-cold lysis buffer containing 8 M urea, 50 mM tris(hydroxymethyl)aminomethane (Tris) hydrochloride pH 8, 10 mM Na 4 (PO 4 ) 2 , 1 mM phenylmethylsulfonylfluoride, 1 mM Na 3 VO 3 and 1 mM β-glycerophosphate (phosphatase inhibitors), and one EDTAfree protease inhibitor tablet per 10 mL (Roche, Indianapolis, IN, USA). Twelve 15-cm dishes of each cell line were harvested to ensure sufficient material; four dishes mixed together were handled as a single biological/workflow replicate. For immunoprecipitation experiments, cells were grown in duplicate with reversed SILAC labels-one Blight^replicate and one Bheavyr eplicate for each cell line. BHeavy^lysine in this experiment was the 13 C 6 isotope. These cells were harvested in a lysis buffer containing 1% NP-40 (Tergitol) from Sigma (St Louis, MO, USA), 20 mm Tris pH 8.0, 137 mM NaCl, and protease and phosphatase inhibitors as above.
Cell lysis and protein digestion
Lysates were sonicated three times for 1 min each with a 2-min rest in between, then centrifuged at 3000 g at 4°C for 10 min. Protein concentration was determined in the supernatants by the bicinchoninic acid assay (Thermo Fisher Pierce, Waltham, MA, USA). For discovery phosphoproteomics, 2 mg of lysates from each cell line were mixed 1:1, reduced with 5 mM dithiothreitol, and alkylated with 14 mM iodoacetamide. The alkylation reaction was quenched with an additional 5 mM dithiothreitol, then the lysates were diluted with 50 mM ammonium bicarbonate to less than1.6 M urea. Bovine N-tosyl-L-phenylalanine chloromethyl ketone-treated trypsin (Sigma) was added at 1:50 enzyme to substrate (mg/mg) along with 5% trifluoroethanol before overnight incubation at 37°C. Digests were quenched with 0.4% trifluoroacetic acid (TFA). We set aside 500-μg aliquots for analysis of the nonenriched proteome and desalted the remaining 3.5 mg of peptides on 100 mg C 18 Sep-Pak cartridges (Waters, Milford, MA, USA) before phosphopeptide enrichment.
Phosphopeptide enrichment and fractionation
Phosphopeptides were enriched with use of both IMAC and TiO 2 beads to enhance coverage, since the two chemistries have been reported to enrich complementary subproteomes [14, 15] . Digestions were performed in triplicate on two occasions, once for each enrichment method. IMAC was performed three times sequentially, with the second and third enrichments mixed together, as described by us previously [15, 16] . Briefly, desalted peptides from 3.5 mg of lysate were resuspended in loading buffer [40% acetonitrile (ACN), 25 mM formic acid (FA) in water] and mixed with 30 uL of prepared PHOS-Select IMAC beads (Sigma). Beads and peptides were incubated for 1 h with shaking at room temperature. The supernatant from the first IMAC enrichment was immediately added to fresh beads to begin the second IMAC enrichment. Similarly, the supernatant from the second IMAC enrichment was added to fresh beads to begin the third enrichment. Beads with bound peptides were rinsed three times in loading buffer, and then phosphopeptides were eluted by our shaking them for 5 min in 50 mM K 2 HPO 4 , adjusted to pH10 with NH 4 OH. This elution step was repeated twice, and the combined eluates were acidified with FA.
TiO 2 enrichment was performed twice as previously reported [15, 17] . Bulk 5-μm Titanosphere particles were purchased from GL Sciences USA (Torrance, CA, USA). Desalted peptides (from 3.5 mg of lysate) were resuspended in a solution of 65% ACN, 2% TFA, and saturated glutamic acid. Each replicate was mixed with 5.6 mg of TiO 2 beads and shaken for 20 min at room temperature. Supernatants were removed and immediately added to fresh beads for the second enrichment. Beads with bound phosphopeptides were first washed in 65% ACN, 0.5% TFA for 20 min with shaking, and then were washed twice in 65% ACN, 0.1% TFA for another 20 min with shaking. Phosphopeptides were eluted by shaking them for 20 min in 300 mM NH 4 OH, 50% ACN, then twice with 500 mM NH 4 OH, 60% ACN. The eluates from these three steps were combined and acidified with FA.
Hydrophilic-lipophilic balanced (HLB) reversed-phase SepPak cartridges (Waters, Milford, MA, USA) were used for highpH reversed-phase fractionation of peptides. All solvents used for HLB fractionation contained aqueous 10 mM ammonium bicarbonate at pH 10, with ACN added as indicated. Peptides were pH adjusted by addition of 100 mM ammonium bicarbonate to a final concentration of 20 mM, then loaded onto cartridges with 1% ACN, 99% 10 mM ammonium bicarbonate and rinsed with the same buffer. Peptides were then eluted with 5%, 10%, 15%, 20%, 25%, 30%, 35%, and 80% ACN. For unmodified proteome analysis, a 500-μg aliquot of nonenriched peptide was prepared as eight fractions. The HLB fractions generated from each of the batches of IMAC-and TiO 2 -enriched peptides (IMAC-1, IMAC-2&3, TiO 2 -1, and TiO 2 -2) were mixed to make four fractions, or 16 phosphopeptide fractions in total. HLB fraction 1 (5% ACN) was mixed with HLB fraction 5 (25% ACN), HLB fraction 2 (10% ACN) was mixed with HLB fraction 6 (30% ACN), HLB fraction 3 (15% ACN) was mixed with HLB fraction 7 (35%) ACN, and HLB fraction 4 (20% ACN) was mixed with HLB fraction 8 (80% ACN). After acidification with FA and vacuum drying to remove ACN, all fractions were desalted by ZipTip before LC-MS/ MS analysis.
LC-MS/MS analysis
LC-MS/MS analyses were performed with a 90-min analytical gradient on a 100 μm × 10 cm C 18 column coupled to a Thermo Q-Exactive mass spectrometer. All analyses were performed in technical duplicate. Solvent A consisted of 0.1% FA in water and solvent B was 0.1% FA in ACN. The flow rate was kept at 1.2 μL/min with the column heated to 40°C. Desalted phosphopeptide-enriched fractions were resuspended in 8 μL of 2% ACN with 0.1% FA and 2 μL was injected on-column. IMAC-enriched fractions were separated on a 2% ACN to 30% ACN gradient. TiO 2 -enriched fractions were separated with a gradient from 2% ACN to 25% ACN. Nonenriched samples were resuspended to 1 μg/μL after desalting; 1 μL was injected on-column. The gradients used for nonenriched HLB fractions differed by the fraction number. The fractions generated with 5%, 10%, 15%, and 20% ACN used a 2% ACN to 30% ACN linear gradient; the fractions generated with 25% ACN and 80% ACN ran from 15% ACN to 40% ACN in 85 min; and the fractions generated with 30% ACN and 35% ACN used a 2% ACN to 40% ACN gradient. Unfractionated, nonenriched samples were analyzed with a 2% ACN to 40% ACN gradient.
The mass spectrometer was operated in data-dependent MS/MS mode with a top-12 method. Dynamic exclusion was set to 30 s and charge 1+ ions were excluded as well. Cysteine carbamidomethylation was a fixed modification, and oxidized methionine was a variable modification. Phosphorylation of serine, threonine, and tyrosine residues were allowed for enriched fractions. Two missed cleavages were allowed, and Trypsin/P was selected as the enzyme. The Bfirst search^precursor mass tolerance was set to 20 ppm, the Bmain search^tolerance was set to 10 ppm, and the fragment mass tolerance was set to 50 ppm. The Bfirst search^and Bmain search^precursor tolerances are parameters specialized to MaxQuant. SILAC ratios were calculated with use of the Bhighest change^setting. A 1% false discovery rate (FDR) was applied at the peptide and protein levels.
BHeavy/light^ratios were converted to SW620/SW480 ratios, then log 2 -transformed. Phosphosites were quantified at the peptide level, requiring at least two SILAC measurements per peptide. The phosphosite localization probability was calculated in MaxQuant. Only class I phosphosites (those with 75% localization probability or better) were considered [18] . For nonenriched fractions, a minimum of two unique peptides were required for protein quantification. Phosphopeptide ratios were corrected for changes in protein abundance by subtraction of the corresponding nonphosphorylated protein log 2 -fold change. Altered regulation of phosphosites was determined by Bonferroni-corrected t tests with α = 0.05. The complete MS dataset is available from the ProteomeXchange Consortium via the PRIDE partner repository under the dataset identifier PXD003708.
Network analysis was performed with the STRING database, version 9.1 (http://string-db.org). UniProt identifiers from 139 protein-abundance-corrected, significantly altered phosphoproteins were submitted for analysis, of which 124 contained a match in the database. Protein-protein interactions were mapped with the website's Bhigh confidence^setting, which represents 70% confidence or better in each interaction. For ease of visualization, disconnected protein nodes were excluded from the relevant figure. Gene Ontology (GO) term enrichment analysis was performed with STRING's embedded tools. The human genome was set as the background dataset from which to measure enrichment. GO terms were considered significantly enriched against the background human genome with FDRadjusted p values greater than 0.01.
Antibodies, immunoprecipitation, and Western blots
Lysates were separated on sodium dodecyl sulfate-polyacrylamide gel electrophoresis mini gels, and proteins were transferred to nitrocellulose membranes for 1.5-2 h at 30 V. Rabbit polyclonal antibodies anti-eIF4E transporter (anti-4E-T) (ab55881) and anti-eIF4E (ab1126) were purchased from Abcam (San Francisco, CA, USA).The anti-4E-T antibody was either diluted 1:500 in 5% w/v milk in phosphatebuffered saline and incubated for 1 h at room temperature or used at 1:1000 overnight at 4°C. Anti-eIF4E antibody was diluted 1:1000 in 5% w/v milk in phosphate-buffered saline and incubated with membranes for 1 h at room temperature. An anti-β-actin antibody (Cell Signaling Technologies, Danvers, MA, USA) was used at 1:750 dilution in 5% bovine serum albumin and Tris-buffered saline-Tween 20. Membranes were incubated with primary antibody for 1 h at room temperature (or overnight at 4°C for β-actin), and then with horseradish peroxidase linked anti-rabbit secondary antibody (Jackson Laboratories, Bar Harbor, ME, USA) for 1 h at room temperature. Bands were visualized with chemiluminescent substrate (Thermo Fisher Pierce).
For immunoprecipitation, 35 μL anti-4E-T antibody was incubated with 350 μg of mixed SILAC lysate for 4 h at 4°C. After this incubation, 175 μL Dynabeads Protein A (Life Technologies, Grand Island, NY, USA) was added and the mixtures were rotated for 1 h at 4°C. After the beads had been washed three times in lysis buffer, the target protein was eluted twice from the beads by heating the beads to 70°C for 10 min in a buffer containing 1% sodium dodecyl sulfate, 50 mM Tris pH 8, and 100 mM dithiothreitol. One tenth of the eluate was retained for Western blot confirmation of pulldown. Eluates were loaded directly onto Amicon 30,000 molecular weight cutoff spin filters (Millipore, Darmstadt, Germany) for filter-aided sample preparation digestion [19] . Briefly, loaded samples were centrifuged at 14,000 g and the samples were alkylated with 50 mM iodoacetamide at room temperature for 20 min in the dark. The filters were then washed three times with 400 μL 8 M urea and then washed three times with 400 μL 25 mM ammonium bicarbonate. Trypsin was mixed with 25 mM ammonium bicarbonate buffer and added to the filters in a 1:30 enzyme-to-substrate ratio. Samples were digested on-filter for 12 h and peptides were collected by centrifugation. The peptides were then desalted on StageTips for quantitative multiple reaction monitoring analysis.
Targeted phosphosite stoichiometry determination
The phosphopeptide APpSPPLSQVFQTR on 4E-T (pSer564) was selected for targeted phosphosite stoichiometry determination. The corresponding non-phosphopeptide and the proteotypic peptide ESSHSGVVLSVEEVEAGLK were also selected for monitoring. A complete list of transitions is given in Table S1 . Approximately 7 μg of desalted, dried peptides was resuspended in 15 μL of 5% ACN, 0.1% FA, and 2 μL was injected on-column. Three replicate injections per biological sample were used. The 100 μm × 10 cm C 18 column was operated at 500 nL/min with a gradient from 2% ACN to 38% ACN in 60 min. A QTRAP 5500 system detected the peptides in multiple reaction monitoring mode with dwell times of 15 ms. The fractional phosphorylation occupancy for each of the target sites was determined with use of the corresponding SILAC peptide as an internal standard. The phosphorylation rate can be calculated when the SILAC ratios for the phosphopeptide, cognate non-phosphopeptide, and an unrelated peptide representing the total protein amounts are known [20] . The complete calculations are detailed in the electronic supplementary material. In brief, phosphorylation occupancy % ð Þ ¼ phosphopeptide peak area phosphopeptide peak area þ non-phosphopeptide peak area ð Þ Â 100:
This can be calculated from the SILAC ratios as shown:
phosphopeptide L copy number non-phosphopeptide L copy number ¼ protein ratio−non-phosphopeptide ratio phosphopeptide ratio-protein ratio ;
phosphopeptide H copy number non-phosphopeptide H copy number ¼ phosphopeptide ratio Â protein ratio−non-phosphopeptide ratio ð Þ non-phosphopeptide ratio Â phosphopeptide ratio−protein ratio ð Þ ;
occupancy % ð Þ ¼ phosphopeptide copy number non-phosphopeptide copy number 1 þ phosphopeptide copy number non-phosphopeptide copy number ;
where subscripts H and L represent Bheavy^and Blightr espectively.
Results and discussion
Combined IMAC and TiO 2 enrichment strategy and normalization to the proteome makes possible detection of widespread changes to the metastatic phosphoproteome. The constitutive phosphorylation differences between SW480 and SW620 cells were examined by comprehensive phosphoproteomic profiling. SILAC-labeled samples were mixed, digested, and subjected to IMAC or TiO 2 enrichment for phosphoproteomic analysis. A portion of the sample was not enriched for phosphopeptides and was analyzed for protein abundance levels. A flowchart of the experimental design is shown in Fig. 1 .
Combining IMAC and TiO 2 enrichment strategies into one workflow allowed greater phosphoproteome coverage than with either method alone. Our previous work demonstrated that multiple rounds of enrichment, performed sequentially, p r o v i d e d e ffi c i e n t e n r i c h m e n t a n d r e c o v e r y o f phosphopeptides [15, 16] . Three rounds of IMAC enrichment yielded 4331 phosphopeptides, 30% of the total identifications. TiO 2 enrichment was much more efficient, with 86% phosphopeptides in the first enrichment and 6567 phosphopeptides identified overall from two enrichment steps. Of the confidently localized and quantified phosphosites, 56.6% were identified uniquely by one enrichment method or the other. For 23% of the quantified phosphopeptides, biological triplicate SILAC measurements were possible only when both enrichment chemistries were considered together.
Unique peptide identifications in IMAC-and TiO 2 -enriched fractions were plotted by high-pH reversed-phase (HLB) fraction as shown in Fig. 2 . Total peptide identifications were distributed equally across HLB fractions. This is especially visible in the IMAC-enriched fractions, where approximately 2000 unique peptides were identified in each fraction. Figure 2 also illustrates the relative contributions of each round of enrichment. The first-round TiO 2 enrichment fractions contained nearly 90% phosphorylated peptides, with much lower specificity in the second round. As fewer total peptides were detected in the second-round TiO 2 enrichment fractions, the data suggest first-round TiO 2 enrichment efficiently depletes most of the peptides that can bind specifically. With IMAC, the first round of enrichment recovered a tiny percentage of phosphopeptides, but the second and third rounds (combined) performed a bit better, with close to 50% specificity. This performance is not consistent with previous observations. After troubleshooting and purchasing new resin, we concluded that this was due to batch-to-batch reproducibility problems with the product. In fact, the old beads outperformed fresh beads. These results show that this IMAC product requires multiple rounds of enrichment to achieve useful levels of phosphoproteome coverage, and the optimized protocol is not consistently robust to manufacturer batch-to-batch variability. TiO 2 chemistry provides the best phosphoproteome coverage in a single step, and addition of a second-round TiO 2 enrichment enhances this coverage modestly, with 18% of TiO 2 phosphopeptide identifications contributed by the second round.
It has been reported by us and others that IMAC and TiO 2 enrich distinct subproteomes [14, 15] . To explore this differential chemistry, we examined the length, isoelectric points, and grand average hydropathy (GRAVY) values of all of the unique peptide sequences identified by IMAC enrichment, TiO 2 enrichment, or without enrichment. The nonphosphorylated peptide spectral matches were aggregated separately from the phosphorylated peptide spectral matches for this analysis, which is summarized in Fig. 3 . IMAC-and TiO 2 -enriched phosphopeptides were generally of similar length, had similar isoelectric point distributions, and had similar hydrophobicities (GRAVY values). The median phosphopeptide enriched by IMAC is slightly longer and more hydrophilic than that enriched by TiO 2 , in agreement with our previous findings. However, the nonphosphorylated peptides reveal distinct patterns. The nonphosphorylated peptides found in TiO 2 fractions were almost exclusively acidic, with isoelectric points less than 5.0, whereas IMAC-enriched nonphosphorylated peptides followed the isoelectric point distribution of the unmodified tryptic proteome. Both IMAC and TiO 2 enriched peptides with lower GRAVY values (more hydrophilic) than the tryptic proteome. Finally, the median nonphosphorylated peptide identified in IMAC fractions was just slightly longer than the median tryptic peptide identified in the unenriched proteome analysis. In fact, many additional missed-cleavage peptides were detected in the IMAC-enriched fractions in comparison with the TiO 2 -enriched or unenriched fractions (Fig. S1 ). In short, TiO 2 specifically co-enriches acidic nonphosphorylated peptides alongside the target phosphopeptides, whereas contaminating unmodified peptides in IMAC fractions are truly nonspecific and largely resemble the general proteome.
Only a handful of other authors have used high-pH reversedphase chromatography in phosphoproteomic workflows, but it has performed favorably against traditional chromatography techniques so far [21] [22] [23] . These groups primarily used ammonium formate buffers at pH 10 with C 18 columns. Song et al. [21] showed that the orthogonality of high-pH reversed-phase chromatography as compared with traditional low-pH reversedphase chromatography was improved by the pooling of nonadjacent fractions. That work was the first to demonstrate the reversed phase-reversed phase approach for phosphopeptide analysis. Ficarro et al. [22] developed reversed phase-reversed phase and reversed phase-strong anion exchange-reversed phase workflows for phosphopeptide analysis that avoided the use of any specific phosphopeptide enrichment chemistry, such as IMAC or TiO 2 . They found phosphopeptides, especially multiphosphopeptides, were weakly retained on C 18 at high pH without the use of specialized ion-pairing reagents, such as tetrapropylammonium salts. As we did not examine the flow-through material from the HLB cartridges used in this study, we cannot rule out the loss of phosphopeptides from poor retention; however, this work and our previous work shows phosphopeptides were eluted evenly across all fractions, from 5% ACN to 80% ACN. In a workflow similar to that described here, Batth et al. [23] fractionated peptides with high-pH reversed-phase chromatography and then enriched phosphopeptides with one or two consecutive rounds of TiO 2 enrichment. They also noted that the C 18 column degraded significantly with each use when ammonium formate was used as the solvent additive. This problem was solved by replacement of the solvents with NH 4 OH. In contrast, the present work avoided this problem by using single-use HLB cartridges. To our knowledge, ours is the only workflow using benchtop solid-phase extraction for reversed-phase fractionation. This strategy provides a simple, low-cost alternative for laboratories that do not have access to a dedicated high-performance LC system and fraction collector. The capability to fractionate multiple samples in parallel confers significant time savings as well, especially as the number of samples increases. From 8802 phosphopeptides identified, 1759 distinct sites were quantified and localized in all three biological replicates. Good overlap of quantified phosphopeptides among the three biological replicates was obtained from both the IMAC workflow and the TiO 2 workflow (Fig. S2) . These 1759 quantified phosphosites mapped to 1114 proteins (Fig. 4a) .
Phosphosite SILAC ratios were corrected for differences in protein expression with use of values from the nonphosphorylated proteome. The utility of this strategy has been successfully demonstrated in yeast [24] . To maximize the number of corrected phosphosites calculated, protein-level data were included when at least two SILAC peptides were quantified in one or more biological replicates. Using 2922 protein groups meeting these criteria, we normalized 454 of the 1114 phosphoproteins (Fig. 4a ). This included 815 of the 1759 quantified phosphosites. From the phosphosites corrected for protein expression, a ±1.5-fold change cutoff, which corresponds to 0.586 on a log 2 scale, was applied after t testing. This detected 108 phosphosites with increased phosphorylation in SW620 cells compared with SW480 cells, and 86 sites with decreased phosphorylation (Fig. 4b) . A more stringent twofold cutoff (1.0 on a log 2 scale) was applied to the noncorrected phosphosites, yielding 58 sites upregulated and 114 sites downregulated. Volcano plots of the corrected and noncorrected datasets are shown in Fig. 4b . After the dataset had been split, the corrected and the noncorrected phosphosites were analyzed as two distinct groups. Corrected phosphosite, noncorrected phosphosites, and proteinlevel quantification details are given in Tables S2, S3 , and S4.
GO and network analysis
Pathway and GO analyses were performed with the significantly altered, corrected phosphosites. Both upregulated and downregulated sites were analyzed together, as any given phosphosite may have either an Bactivating^or an Binhibitory^role in regulating a protein's known functions. Among the most significantly enriched GO molecular functions were poly(A) RNA binding, kinase binding, and mRNA 5' untranslated region binding ( Table 1) . The top cellular component terms included anchoring and adherens junctions, alongside nuclear components and the nuclear pore complex. The enriched biological processes included cellular component disassembly, mitotic cell cycle, mitotic nuclear envelope disassembly (all nuclear pore complex proteins), and RNA transport and establishment of RNA localization. The complete list of enriched GO biological processes, molecular functions, and cellular components is given in Tables S5,  S6 , and S7.
Plotting of significantly altered phosphosites in STRING revealed several functional clusters that tended to align with GO annotation information [25] (Fig. 5) . One cluster centered around mitosis and functions related to the cell cycle, including such phosphoproteins as structural maintenance of chromosomes 4, topoisomerase IIA, spindle and kinetochore associated complex subunit 3, anillin, and marker of proliferation Ki-67. This perturbation in mitotic signaling is consistent with the more aggressive growth of the SW620 cell line. Likewise, since the SW620 cells are known to have greater migratory capacity [10] , it was expected that numerous phosphoproteins related to cytoskeletal organization, migration, and adhesion would be differentially regulated. Phosphoproteins in this cluster include δ-catenin, tight junction protein 2, zyxin, integrin β 4 , and desmoplakin.
The remaining clusters included nuclear pore complex proteins, mRNA biogenesis and splicing factors, and translation initiation factors alongside ribosomal proteins. Messenger RNA (mRNA) biogenesis, translation, and related processes are tightly regulated functions required by all cells, but a growing body of evidence has revealed that their dysregulation contributes to carcinogenesis and, to a lesser extent, metastasis [26, 27] . Human transcripts must compete for a limited pool of the cap-binding protein eIF4E, which is one of several factors required for export to the cytosol through the nuclear pore complex. Overexpression of eIF4E contributes to oncogenic transformation in a wide array of cancers and plays a role in metastatic progression [28] [29] [30] . The regulatory functions of the phosphosites we observed on nucleoporins 88, 133, 153, and 210 are currently unknown, but multiple nucleoporins have been observed to modulate the transport and ultimate translational efficiency of specific cancerrelated mRNA transcripts, as reviewed in recent articles [31] [32] [33] . In short, there is a growing catalog of mechanisms that determine the translation rate of specific mRNA transcripts, and evidence that cancer cells hijack many of these mechanisms for survival [34] . There has been significantly less research tying these mechanisms to metastasis. Our results are largely in agreement with previous proteomic studies of the SW480 and SW620 cell lines. Ghosh et al. [12] found that SW620 cells, as compared with SW480 cells, overexpressed several proteins involved in migration, adhesion, and cytoskeletal structure with novel roles in metastasis. Our network analysis highlights these same processes and illustrates the role played by phosphorylation-mediated signaling. A comparison of the secretomes of these cell lines found trefoil factor 3 and growth/differentiation factor 15 were upregulated in SW620 cells [13] . Neither study specifically highlighted the role of mRNA biogenesis or decay; however, in our analysis, these processes were modulated exclusively at the phosphorylation site level rather than by protein abundance changes. Table 2 shows a selection of the phosphosites with the greatest fold changes and significance levels. Many of these phosphoproteins have known roles in the functional clusters observed in the STRING analysis and in cancer progression. AHNAK and septin 9 have been shown to be essential to pseudopod formation, migration, and epithelial-mesenchymal transition in metastatic cancer cell lines [35] . Vinculin, a component of focal adhesions, contains the single most downregulated phosphosite in this study. Loss of vinculin expression has been shown to correlate with increased migration, invasiveness, and metastatic outcomes [36] . Both this work and that of others have reported that SW620 cells express more vinculin than SW480 cells [36] , but the function of the phosphosite identified in this work is currently unknown. Nucleophosmin, which contains multiple highly upregulated phosphosites, plays important roles in ribosome biogenesis, centrosome duplication, and apoptosis following DNA damage [37] . It has been reported to be overexpressed in metastatic colon cancers relative to primary tumors and normal tissues and to contribute to invasive behavior [38] . Pertaining to mRNA biogenesis and function, heterogeneous nuclear ribonucleoproteins A2/B1 [39] , eukaryotic translation initiation factor 4G (eIF4G), eIF2S2, and ribosomal proteins L12 and L4 all contain highly significant phosphosites as well. Many of the phosphoproteins listed in Table 2 and the specific sites identified would be worth further investigation to tease out the specific mechanistic roles of each site.
SW620 cells show significant phosphorylation changes on critical cancer proteins
Besides highlighting particularly upregulated and downregulated phosphosites, Table 2 also illustrates an interesting analytical observation. In certain cases, the large site fold changes are driven by phosphopeptide level changes, whereas others are driven by protein-level changes. Some phosphoproteins observed were extremely stable at the protein level but had highly significant phosphopeptide ratios, such as histones H1.4 and H1.5 and ribosomal proteins L4 and L12. In other cases, we observed modest phosphosite changes but dramatic protein differences. For example, septin 9 pSer11 and nucleophosmin pSer137 and pSer139 have very modest phosphopeptide biogenesis-related clusters. eukaryotic translation initiation factor 4E transporter (EIF4ENIF1; 4E-T) and decapping protein 1A (DCP1A), shown as diamonds, had missing protein-level information but had Gene Ontology annotations that associated them with the mRNAlifecycle-related clusters. The NELF complex stands for negative elongation factor complex. All the gene abbreviations shown are listed alongside their full protein names in Supplemental Table S2 SW620/SW480 ratios, but exhibit dramatic protein-level changes that result in a significant corrected phosphosite ratio. This situation implies that even though there are fewer copies of these proteins in SW620 cells, the fraction of copies that are phosphorylated at the indicated sites increased. Phosphosites like these whose occupancy changed in the opposite direction of protein abundance would not have been detected had the unmodified proteome not been analyzed.
Metastatic cells show dysregulation in mRNA biogenesis and translation
The most significantly upregulated phosphosite measured in SW620 cells as compared with SW480 cells was pSer2 of eIF2S2. Eukaryotic translation initiation factor 2 subunit 1 uses a GTP to GDP hydrolysis to catalyze docking of the methionine transfer RNA to the ribosome preinitiation complex in the final step of translation initiation, and eIF2S2 participates in the exchange of the GDP for a fresh GTP. Blocking phosphorylation at Ser2 by mutation to alanine has been shown to cause a global translation slowdown [40] . A dramatic increase in phosphorylation at this site in the metastatic cell line suggests an increased rate of global translation in SW620 cells. Consistent with our observations, a 2006 microarray study of the SW480 and SW620 cell lines that used both total cellular mRNA and polysome profiling identified upregulation of transcripts related to RNA transport, transfer RNA metabolism, and translational machinery [41] . Other critical transcripts pertained to cell cycle, viability, and apoptosis. The study authors found more than 80% of the inter-cell-line variation was represented exclusively at the polysome level, suggesting that adaptations required for metastasis were better achieved by modulation of the translational efficiency of particular transcripts rather than by simple change of the copy number.
The cap-binding protein eIF4E has previously been reported to be overexpressed in many cancers and has been tied to oncogenesis and progression [29, 42, 43] . To evaluate whether oncogenic overexpression of eIF4E might account for the general overactivation of translation in SW620 cells, the abundance level of the protein was examined. The data demonstrated, however, that this Blimiting reagent^of translation is just slightly more abundant in SW480 cells than in SW620 cells, with an average log 2 ratio of -0.46 (three replicates). Western blots against eIF4E performed on the original SILAC samples produced a similar result (Fig. 6) . Therefore, the observed global mRNA regulatory perturbations occur despite fewer copies of eIF4E being available to the SW620 cells.
American Type Culture Collection reports that both SW480 cells and SW620 cells have driver KRAS, HRAS, and NRAS mutations. Ras signaling through extracellularsignal-regulated kinase, phosphatidylinositol 3-kinase/AKT, and mammalian target of rapamycin complex 2 is known to activate cap-dependent translation, especially by acting on the FC log 2 fold change (SW620/SW480).
eIF4E-eIF4G-eukaryotic translation initiation factor 4A-mRNA cap complex [43] . Thus, upregulated translation would be expected to be a natural consequence of mutant Ras. However, since SW480 and SW620 cells both show constitutive Ras activation, this pathway is not sufficient to explain the deregulation of translation specific to the metastatic cells. Despite the extensive research that has been done to understand the regulation of translation, the stimuli that are responsible for the difference between SW480 and SW620 cells' phosphorylation in this network are unclear.
Messenger RNA degradation phosphoproteins 4E-T and decapping protein 1A
After we had observed broad phosphorylation-level regulatory alterations to mRNA biogenesis and translational circuits, the next question was whether any of the noncorrected phosphopeptides had GO annotations to connect them to this network. This analysis yielded three such phosphopeptides: APpSPPLSQVFQTR (Ser564) of 4E-T as well as L R L p T P Q H D Q I Q T Q P L G K ( T h r 4 0 1 ) a n d KASpSPpSPLTIGTPESQR (Ser522/523, Ser525) of mRNA decapping protein 1A (DCP1A) ( Table S8 ). In the latter peptide, pSer525 was localized with 98% confidence but the second phosphorylation could be attached at either 522 or 523. The 4E-T peptide containing pSer564 was found to be about twice as concentrated in SW480 cells as in SW620 cells; the two DCP1A phosphopeptides were twofold upregulated in the SW620 cell line in the discovery experiment. Since no unmodified peptides for these proteins were identified in our proteome analysis, these phosphopeptides could not be normalized for protein abundance. 4E-T has been shown to recruit mRNA cap-binding protein eIF4E to processing bodies, where the mRNA is either sequestered or degraded. A recent report showed c-Jun N-terminal kinase phosphorylates 4E-T at sites distinct from Ser564 on an increase in the level of reactive oxygen species, which leads to an increase in processing body size [44] . The function of pSer564
has not yet been reported, nor have there been any previous reports of 4E-T function changing in correlation to metastasis.
DCP1A acts as part of a larger decapping complex to remove the protective 5′ cap from mRNA marked for degradation. It operates primarily in the cytoplasm and has been shown to interact with 4E-T in processing-bodies under stress-triggered -Jun N-terminal kinase signaling [45] . DCP1A has also been reported to be a target of transforming growth factor β signaling [46] . The specific roles of pSer525 and pThr401 are uncharacterized; however, the C-terminal domains containing these sites (380-470, 470-582) have been shown to contribute to processing body localization [47] . The protein is also known to become hyperphosphorylated during M phase, including at Ser522/523. Alanine mutants of these two sites have been shown to interfere with processing body localization but do not completely abolish it. In contrast to its well-recognized role in mRNA decay, DCP1A has not previously been linked to cancer progression.
It was unclear whether the apparent phosphosite changes on 4E-T and DCP1A were artifacts of protein abundance changes or if they represent true differences in site stoichiometry. Western blots indicate that 4E-T is expressed at similar levels in the two cell lines (Fig. 6 ), so we proceeded to measure the absolute site stoichiometry at Ser564 by selected reaction monitoring (SRM). 4E-T was prepared for SRM analysis by our immunoprecipitating it in duplicate from pooled SILAC SW480 and SW620 lysates (Fig. 7a ). An immunoblot showed the target protein was pulled down efficiently (Fig. S1 ). SRM revealed that 4E-T Ser564 was 55-88% phosphorylated in SW480 cells and 65-79% phosphorylated in SW620 cells; there was no significant change between cell lines. Technical variation was relatively low, with coefficients of variation between 4% and 10% (Table S9 ). The phosphopeptide SW620/SW620 ratios measured by SRM trended in the same direction as those measured in the discovery experiment, but with a smaller magnitude (Table S9) . Thus, a modest decrease in protein copy number best explains the differences in phosphorylation initially observed between the cell lines. Although this site does not correlate to metastatic status, the high fractional occupancy at this site does suggest a critical function for pSer564 in logarithmically growing cells. Furthermore, finding the site occupancy unchanged between cell lines reiterates the importance of considering protein abundance changes in phosphoproteomic experiments.
As with 4E-T, DCP1A was examined first by immunoblot, which revealed no cell-line-dependent difference in protein abundance. However, DCP1A from SW620 cells exhibited a gel mobility shift that is consistent with hyperphosphorylation. This high degree of modification prevented the selection of tryptic proteotypic peptides suitable for SRM analysis; therefore, DCP1A was not amenable to targeted site stoichiometry analysis. When hyperphosphorylation is present or suspected, it becomes especially crucial to avoid the selection of peptides Immunoblots against 4E-T, DCP1A, and eukaryotic translation initiation factor 4E (eIF4E) in the SILAC-labeled lysates used for proteome and phosphoproteome analysis. b-Actin served as the loading control. Triplicate lanes of each biological replicate lysate were prepared across two membranes; a representative image is shown containing serine and threonine. DCP1A contains just two such tryptic peptides, and neither of these was detectable in immunoprecipitates.
The immunoprecipitation-SRM analyses of 4E-T and DCP1A illustrate the ongoing challenges for targeted phosphoprotein analysis, and more broadly for targeted analysis of any posttranslational modification. Many phosphoproteins of biological interest are found at relatively low abundance in vivo and thus require immunoprecipitation or other enrichment from tissue or cellular extracts. Although a targeted analysis meant to simply measure total protein concentration can select among the peptides most amenable to SRM analysis, this choice does not exist for a phosphosite target. If multiple-phosphorylation isomers are possible for the peptide(s) of interest, these must all be surveyed. Site stoichiometry determination adds an extra challenge. The occupancy of some sites may be highly variable in vivo. When the occupancy is either very high or very low, either the phosphopeptide or its counterpart non-phosphopeptide must necessarily exist at low abundance. All these factors must be taken into consideration during targeted assay design. Fundamentally, adequate sensitivity for all relevant peptide species is the greatest obstacle to meaningful assay results.
Conclusion
This is the first comparison of the constitutive phosphoproteome of the colon cancer stage II and stage III cell lines SW480 and SW620. With 815 proteinnormalized phosphosites quantified, along with many novel phosphosites detected as well, this work should provide a valuable resource to other researchers. Comprehensive phosphopeptide profiling shows that the metastatic cell line is distinguished from the primary tumor cell line by differential regulation in cellular adhesion, cytoskeletal structure, mitosis, mRNA transport, and translation. Since many of the sites detected in this analysis are not functionally characterized, additional work will be required to tease out the specific relationships between the driver kinases, the phosphorylation of translation proteins, and metastatic phenotypes. Further investigation will be required to reveal how regulation of translation contributes to the metastatic phenotypes that the SW620 cell line displays, as well as to generalize these findings to other cell lines.
In summary, this work illustrates the breadth of deregulation in the constitutive phosphoproteome of metastatic cells, especially in the mRNA translation machinery. Our findings suggest there is much left to investigate regarding the selective advantage that metastatic cells gain from translation deregulation. Likewise, it remains unclear which signaling stimuli are responsible for the level of deregulation that is observed. More straightforward explanations for translation perturbations, such as overexpression of eIF4E or activated Ras, are not enough to differentiate the two isogenic cell lines, so there may be uncharacterized factors that are influencing translation in these cell lines. Finally, this work suggests that metastatic cells may be uniquely susceptible to translation inhibitors. Further work will be required to test whether this hypothesis will be borne out. 
